Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Markets React To The Jobs Data, War Clouds
-
Bitcoin Whales Dump Over $2 Billion Worth of BTC after Price Rose Over 30% in a Month
-
Veteran Analyst Peter Brandt Says This Level Is Of "Huge Significance" To Bitcoin
-
United States Cellular Corp. Plunges On Reporting Quarterly Loss, Missing Street View
-
Still Bullish: Billionaire Money Manager Bill Miller Maintains View Bitcoin Will Rise Again Despite FTX Chaos